Global Overactive Bladder Therapeutics Market: Competitive landscape
Pfizer Inc., Johnson & Johnson, Aurobindo Pharma Ltd., Astellas Pharma Inc., Merck & Co. Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Ono Pharmaceutical Co. Ltd., Allergan, AbbVie Inc., Sanofi, Cogentix Medical and Endo International Plc. are the major players of global overactive bladder therapeutics market.
These key players are more focused on the fast growing segment of the market to survive and succeed in a cut throat market scenario. Moreover the market players are focused in collaboration and license agreement which is expected to drive the market growth. For instance, in March 2021 Japanese firm KYORIN Pharmaceutical and Eisai Co. Ltd. signed a license agreement for development and marketing of Vibegron drug as a treatment for overactive bladder syndrome in Thailand, Malaysia, Brunei and the Philippines.
Overactive Bladder Therapeutics Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients